ClaireFVerschraegenMDMS, FACP

Oncology • Columbus, OH

Endocrine Cancer, Gynecologic Cancer, Hematologic Oncology, Melanoma

Director and Professor, Division of Medical Oncology

Join to view full profile

Dr. Verschraegen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Verschraegen's full profile

Already have an account?

Office
2050 Kenny Rd
Fl 4
Columbus, OH 43221
Phone+1 614-293-5066

Fax+1 614-293-9449

Summary

I am a professor of medicine and director of the Division of Medical Oncology in the Department of Internal Medicine at The Ohio State University College of Medicine. I also hold the Diane Nye and Michael Rayden Chair in Innovative Cancer Research at Ohio State and serve as associate director for translational research at Ohio State's Comprehensive Cancer Center.

I am a board-certified medical oncologist who specializes in treating patients with rare cancers, including mesothelioma, metastatic melanoma, sarcomas and gynecologic malignancies. Another of my specialties is the study of new anticancer drugs and treatments for solid tumors. My work has been continuously funded for more than 20 years, including grant support for phase I, II and III clinical trials. I have been appointed by the National Cancer Institute (NCI) to serve on many committees, such as the NCI Gynecological Cancer Steering Committee, which approves the federally-sponsored randomized studies for gynecological cancers.

I was recruited to Ohio State in 2017 from the University of Vermont, where I was a professor of medicine, director of Hematology/Oncology, director of the cancer service line and co-director of the University of Vermont Cancer Center. I earned my master's degree and medical degree at the Université Libre de Bruxelles in Belgium and trained at the Institut Jules Bordet in internal medicine/oncology. I then completed a cancer research fellowship at the Stehlin Foundation for Cancer Research and an internal medicine residency training at the University of Houston, followed by a medical oncology fellowship at The University of Texas MD Anderson Cancer Center.

In my 30 years as an academic medical oncologist, much progress has been made in treating some cancers through novel targeted therapies and immunotherapies, a result of the well-planned clinical and translational studies to which I have devoted the greatest part of my professional life. I am privileged to continue this mis

Education & Training

University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1992 - 1994
University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1988 - 1991
Universite Libre de Bruxelles Faculty of MedicineClass of 1982
Universite Libre de Bruxelles, School of BotanyM.S., Magna Cum Laude, 1977 - 1980

Certifications & Licensure

OH State Medical License 2017 - 2025
TX State Medical License 1993 - 2019
VT State Medical License 2011 - 2018
NM State Medical License 2002 - 2017

Awards, Honors, & Recognition

Marquis Who's Who 2018
US News & World Report 2015
America's Top Doctors Castle Connolly, 2008-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Irwin H. Krakoff, MD, Endowed Green & Gold Professor of Medicine 2011
Excellence in Research Award UNM Health Science Center, 2009
A Women on the Move Honoree 2004
Honored Member, Strathmore's Who is Who 2000
Fellow American College of Physicians, 1999
Certificate of Merit M.D. Anderson Cancer Center, 1994
Research Fund Competition Fellow Recipient Award M.D. Anderson Cancer Center, 1993
Fellow Federation Nationale de la Recherche Scientifique, 1987
Occino-Kernkamp Prize Belgium Association of University Women, 1986
Fellow Belgian American Educational Foundation, 1985
Fulbright Scholar 1985
Scholarship for Studies Abroad Belgian Secretary of Education, 1980
Join now to see all

Clinical Trials

Phase I Study of Capecitabine in Combination With Cisplatin and Irinotecan Start of enrollment: 2003 Apr 01
Completed
Phase 1
Phase II Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC) Start of enrollment: 2003 Apr 01
Completed
Phase 2
Pharmacology Study of Aerosolized Liposomal 9-Nitro-20 (S)-Camptothecin (L9NC) Start of enrollment: 2003 Aug 01
Withdrawn
Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC) Start of enrollment: 2003 Apr 01
Completed
Phase 2
Clinical Benefit of Topoisomerase Downregulation Start of enrollment: 2004 May 01
Completed
Phase 1
Pharmacology Study of Aerosolized Liposomal Start of enrollment: 2003 Apr 01
Withdrawn
Phase 2
Phase IB Study of Gemcitabine, Docetaxel and Bevacizumab in Patients With Soft Tissue Sarcoma Start of enrollment: 2005 Nov 01
Completed
Phase 1
Aerosolized Liposomal Camptothecin in Patients With Metastatic or Recurrent Cancer of the Endometrium or the Lung Start of enrollment: 2003 Aug 01
Completed
Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer Start of enrollment: 2005 Dec 01
Withdrawn
Not Applicable
Cancer Center Trials: Reasons for Low Accrual Rates at One Academic Institution Vs. The Community Setting Start of enrollment: 2005 Jan 01
Completed
Safety and Efficacy Study of Glufosfamide in Previously Treated Advanced Soft Tissue Sarcoma Start of enrollment: 2007 Mar 01
Completed
Phase 2
Safety and Efficacy Study of Glufosfamide in Ovarian Cancer Start of enrollment: 2007 Jan 01
Terminated
Phase 2
S0718 Pazopanib and Temsirolimus in Treating Patients With Advanced Solid Tumors
Withdrawn
Phase 1
Phase II Study of Remeron for Cancer Patients Losing More Than 10% of Their Body Weight Start of enrollment: 2008 Nov 01
Terminated
Phase 2
The Response of Serum 25-Hydroxyvitamin D to Incidental Ultraviolet Light Exposure Start of enrollment: 2008 Nov 01
Completed
Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA) Start of enrollment: 2007 Mar 01
Completed
Phase 2
Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma Start of enrollment: 2008 Sep 01
Completed
Phase 1
Comparison of Standard of Care or Treatment on Protocol Start of enrollment: 2009 Mar 01
Terminated
Not Applicable
Evaluation of the Role of Prostaglandins in Radiation-induced Mucositis Start of enrollment: 2010 Dec 01
Completed
Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma Start of enrollment: 2012 Oct 01
Completed
Phase 1, Phase 2
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma Start of enrollment: 2013 Sep 16
Active, not recruiting
Phase 3
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas Start of enrollment: 2014 Jan 01
Completed
Phase 3
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors Start of enrollment: 2018 Jan 18
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

54 citations
Cyclin E deregulation alters the biologic properties of ovarian cancer cells.
Isabelle Bedrosian, Karen H Lu, Claire F. Verschraegen, Khandan Keyomarsi
Oncogene. 2004-04-08
522 citations
Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies.
Yi-Zhou Jiang, Ding Ma, Chen Suo, Shi Jinxiu, Mengzhu Xue
Cancer Cell. 2019-03-18
20 citations
Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer.
Jeffrey R. Infante, Amita Patnaik, Claire F. Verschraegen, Anthony J. Olszanski, Montaser Shaheen
Cancer Chemotherapy and Pharmacology. 2017-01-17

Journal Articles

PEGylated engineered interleukin-2 (IL-2) CD122-biased immunostimulatory cytokine Cancer immunotherapy
Rogers, S.C., Shah, H., Yin, M., Folefac, E., Lee, R., Verschraegen, C., Drugs of the Future, 1/1/2018
Hypofractioned radiation therapy for early breast cancer regional nodal irradiation - the jury is still out
Hilde Van Parijs, Nele Adriaenssens, Claire Verschraegen, Zineb Dahbi, Vincent Vinh-Hung, Guy Storme, Mark De Ridder, Nam P. Nguyen, Translational Cancer Research, 1/1/2018
Management of high-grade pleomorphic sarcoma with colon metastasis
Conor O'Neill, MD, Jesse Moore, MD, Alexandra Kalof, MD, Carlos Marroquin, MD, Claire Verschraegen, MD, and Ted A James, MD, Journal of Community and Supportive Oncology, 1/1/2017
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K, Ross M, G..., J Clin Oncol, 1/26/2015
Overview of embryonal rhabdomyosarcoma of cervix in women over 40-years-old
Malala Razakanaivo, Nam P Nguyen, Juliette Thariat, Vincent Molinie, Anne-Therese Vlastos, Claire Verschraegen and Vincent Vinh-Hung, World Journal of Obstetrics and Gynecology, 1/14/2015
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf, F. Stephen Hodi, Caroline Robert, Jeffrey S. Weber, Kim Margolin, Omid Hamid, Debra Patt, Tai-Tsang Chen, David M. Berman and Jedd D. Wolchok, J Clin Oncol, 1/10/2015
Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gyn...
Hensley ML, Miller 2, O'Malley DM, Mannel RS, Behbakht K, Bakkum-Gamez JN, Michael H, J Clin Oncol, 1/1/2015
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbe C, Ferraresi V, Smylie M, Weber JS, Maio ..., Lancet Oncol, 1/1/2015
Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial
Maio M, Grob JJ, Aamdal S, Bondarenko I, Robert C, Thomas 2, Garbe C, Chiarion-Sileni V, Testori A, Chen TT, Tschaika M, Wolchok JD, J Clin Oncol, 1/1/2015
Ovarian Cancer - Angiogenesis and Targeted Therapy
Kristsanamon Rittiluechai, Naiyarat Prasongsuk, Vincent Vinh-Hung and Claire Verschraegen, Current Angiogenesis, 1/1/2015
Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimu...
Howard L Kaufman, Robert Hans Ingemar Andtbacka, Frances A. Collichio, Thomas Amatruda, Neil N. Senzer, Jason Chesney, Keith A. Delman, Lynn E. Spitler, Igor Puzanov, ..., J Clin Oncol, 1/1/2014
Regulated intratumoral expression of IL-12 as a basis for combination therapy in melanoma
John J Nemunaitis, Gerald P Linette, Omid Hamid, Sanjiv S Agarwala, Alexander Starodub, Lei Sun, Francois Lebel, John A Barrett, Jonathan Lewis, Journal of Translational Medicine, 1/1/2014
Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials
Wolchok JD, Weber JS, Maio M, Neyns B, Harmankaya K, Chin K, Cykowski L, de Pril V, Humphrey R, Lebbe C, Ann Oncol, 1/10/2013
Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer
Verschraegen CF, Czok S, Muller CY, Boyd L, Lee SJ, Rutledge T, Blank S, Pothuri B, Eberhardt S, Muggia F, Ann Oncol, 1/31/2012
Gynaecological cancers in pregnancy
Morice P, Uzan C, Gouy S, Verschraegen C, Haie-Meder C, Lancet, 1/11/2012
A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies
Bauman J, Verschraegen C, Belinsky S, Muller C, Rutledge T, Fekrazad M, Ravindranathan M, Lee SJ, Jones D, Cancer Chemother Pharmacol, 1/1/2012
Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer
McMeekin S, Patel R, Verschraegen C, Celano P, Burke J 2nd, Plaxe S, Ghatage P, Giurescu M, Stredder C, Wang Y, Schmelter T, Br J Cancer, 1/22/2011
Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen
Verschraegen CF, Arias-Pulido H, Lee SJ, Movva S, Cerilli LA, Eberhardt S, Schmit B, Quinn R, Muller CY, Rabinowitz I, Purdy M, Snyder D, Bocklage T, Ann Oncol, 1/11/2011
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert, Luc Thomas, Igor Bondarenko, Steven O'Day, Jeffrey Weber, Claus Garbe, Celeste Lebbe, Jean-FranÃ§ois Baurain, Alessandro Testori, Jean-Jacques Grob, N..., N Engl J Med, 1/1/2011
Does Ethnicity Influence Response To Docetaxel Based-Chemotherapy For Patients With Castration Resistant Prostate Cancer? The New Mexico Perspective
S. Ravi-Kumar, S. Lee, I. Rabinowitz & C. Verschraegen, The Internet Journal of Oncology, 1/1/2011
Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509
Garland LL, Chansky K, Wozniak AJ, Tsao AS, Gadgeel SM, Verschraegen CF, Dasilva MA, Redman M, Gandara DR, J Thorac Oncol, 1/1/2011
Epidermal growth factor receptor as a biomarker for cervical cancer
Soonthornthum T, Arias-Pulido H, Joste N, Lomo L, Muller C, Rutledge T, Verschraegen C, Ann Oncol, 1/1/2011
Locally advanced cervical cancer: what is the standard of care?
Al-Mansour Z, Verschraegen C, Curr Opin Oncol, 1/13/2010
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T Jr, Grob JJ, Chesney J, Chin K, Chen K, Hoos A, O'Day S..., Lancet Oncol, 1/1/2010
Palifosfamide tromethamine
Rasila, K.K., Verschraegen, C.F., Drugs of the Future, 1/1/2010
Join now to see all

Books/Book Chapters

International Manual of Oncology
Chapter: Ovarian Cancer
Kristsanamon Rittiluechai, Yongli Ji, Karen Lounsbury, Alan Howe, Claire VerschraegenEditors: Ramon Andrade B. Mello.PracticeSpringer Science+Business Media B.V., Dordrecht, The Netherlands2014
International Manual of Oncology
Chapter: Clinical Approach to Advanced Melanoma for Today and Tomorrow
Joanne Monterroso, Yongli Ji, Steve Emmons, Claire VerschraegenEditors: Ramon Andrade B. Mello.PracticeSpringer Science+Business Media B.V., Dordrecht, The Netherlands2014
Lost in Translation - Barriers to Incentives for Translational Research in Medical Sciences
Chapter: Methylation, Methionine and Metaphors. In Lost in Translation - Barriers to Incentives for Translational Research in Medical Sciences
Page 21 - 43Claire Verschraegen and Gary SteinEditors: Rakesh Srivastava, Wojciech Maksymowicz, and Wlodek Lopaczynski.World Scientific Publishing Co., Singapore2014
Breast Surgical Techniques and Interdisciplinary Management
Chapter: "Breast Sarcomas"
Page 555 - 579Anne Marie Wallace, Bret R. Baack, and Claire F. VerschraegenEditors: Frederick M. Dirbas and Carol E.H. Scott-Conner.Springer Verlag, New York, NY2011
ASCO 2009 Educational Book Category: Gynecologic Cancer
Chapter: Challenges in the Management of Invasive Cervical Cancer.
Page 295 - 300Sujana Movva, MD, Michael Gold, MD, Perry Grigsby, MD, and Claire Verschraegen, MD2009
ASCO Educational Book Manuscript, Educational Book - Category: Gynecologic Cancer
Chapter: Challenges in the Management of Invasive Cervical Cancer
Sujana Movva, MD, Michael Gold, MD, Perry Grigsby, MD, and Claire Verschraegen, MD2009
ASCO Educational Book
Chapter: Medical Treatment of Cervical Cancer
Sujana Movva, MD, and Claire Verschraegen, MD2008
Clinical Gynecology
Chapter: Fallopian Tube Carcinoma.
Page 687 - 699Harriet O. Smith, MD, Steven C. Eberhardt, MD, Claire F. Verschraegen, MD, Therese E. Bocklage MDEditors: EJ Bieber.Elsevier2006
Camptothecins In Cancer Therapy
Chapter: Clinical studies of rubitecan (9-nitro 20(S) camptothecin).
Page 207 - 228Hewes H., Smith JA, Verschraegen C.Editors: V. R. Adams and T. G. Burke.Humana Press Inc., Totowa, NJ2005
Principles and Practice of Anticancer Drug Treatment (European Academy of Gynecological Cancer Book Series)
Chapter: Future strategies in the prevention and treatment of gynecological cancers. What gynecologic oncologists should know about chemotherapy.
Claire F VerschraegenEditors: Peter Bosze and Maurie Markam.2005
Principles and Practice of Anticancer Drug Treatment (European Academy of Gynecological Cancer Book Series)
Chapter: Cytotoxic drugs in gynecology oncology. What gynecologic oncologists should know about chemotherapy.
Claire Verschraegen and John BibbEditors: Peter Bosze and Maurie Markam.2005
Malignant Mesothelioma: Advances in Pathogenesis, Diagnosis, and Translational Therapies
Chapter: Clinical Presentation and Natural History of Mesothelioma: Abdominal.
Verschraegen CF, Key C, Hassan R2003
Palliative Care Consultations Series, Focus on Gynecology
Chapter: The assessment and management of advanced cancer of the cervix.
Verschraegen C, Padilla-Paz L, Smith HO, Gorty SG, Liem B, Kaur HEditors: Bruera.Oxford University Press2002
Proceedings of the VIII Meeting of the International Gynecologic Cancer Society
Chapter: Treatment of advanced or recurrent uterine sarcomas.
Verschraegen C, Kudelka A, Kavanagh JEditors: Pecorelli.ISI, Philadelphia, PA2000
Medical Management of Chronic Myelogenous Leukemia
Chapter: Monitoring the BCR changes during CML therapy: The M.D. Anderson Experience.
Page 303 - 316Verschraegen CFEditors: Kantarjian & Talpaz.Marcel Dekker Inc., New York, NY1999
Cancer in Women
Chapter: Progress toward tumor-specific immunity in carcinomas of the ovary and breast.
Page 30 - 53Freedman RS, Kudelka AP, Verschraegen CF, Platsoucas CDEditors: Kavanagh JJ, Singletary S, Pecorelli S, DiPetrillo A, Einhorn N.Blackwell Scientific Publications, Cambridge, MA1998
Cancer in Women
Chapter: Biology of Gynecologic Cancers
Page 3 - 29Verschraegen CF, Dhingra K, Jones LAEditors: Kavanagh JJ, Singletary S, Pecorelli S, DiPetrillo A, Einhorn N.Blackwell Scientific Publications, Cambridge, MA1998
Ovarian Cancer: Controversies in Management
Chapter: Role of hormonal therapy in the management of ovarian cancer.
Page 325 - 341Schwartz PE, Kavanagh JJ, Kudelka AP, Verschraegen CFEditors: Gershenson DM, McGuire WP.Churchill Livingstone Inc., New York, NY1997
Clinics in Geriatric Medicine
Chapter: Gynecologic cancer in the elderly.
Page 363 - 379Termrungruanglert W, Kudelka AP, Edwards CL, Delclos L, Verschraegen CF, Kavanagh JJEditors: Balducci L.W.B. Saunders Company, Philadelphia, PA1997
Am Soc Clin Oncol Educational Book
Chapter: Novel therapy in cancer of uterine cervix.
Page 97 - 102Kavanagh JJ, Kudelka AP, Verschraegen CF1996
Join now to see all

Abstracts/Posters

Carboplatin and Pembrolizumab Chemoimmunotherapy Achieves Remission in Recurrent, Metastatic Sebaceous Carcinoma.
Kodali S, Tipirneni E, Gibson PC, Cook D, Verschraegen C, Lane KA, Ophthalmic Plastic and Reconstructive Surgery, 1/3/2018
Avelumab in patients with previously treated mesothelioma: Updated phase 1b results from the JAVELIN Solid Tumor trial.
Raffit Hassan, Anish Thomas, John J. Nemunaitis, Manish R. Patel, Jaafar Bennouna, Franklin Chen, Jean-Pierre Delord, Afshin Dowlati, Matthew H. Taylor, John D. Powder..., Journal of Clinical Oncology, 1/1/2018
Incidence of ototoxicity in head and neck cancer (HNSCC) patients (pts) receiving concomitant chemo-radiation (CRT) with weekly or triweekly cisplatin (Cis).
Jishu Das, Amy Custer, Dukagjin Blakaj, Matthew O. Old, Songzhu Zhao, Aashish D Bhatt, Stephan Y Kang, Amit Agrawal, Enver Ozer, Jessica Wobb, Robert Rupert, Darrion L..., J Clin Oncol, 1/1/2018
Precision oncology: Results of a phase I study of M2698, a p70S6K/AKT targeted agent in patients with advanced cancer and tumor PI3K/AKT/mTOR (PAM) pathway abnormalities.
Apostolia Maria Tsimberidou, Claire F. Verschraegen, Amy M. Weise, John Sarantopoulos, Gilberto Lopes, John J. Nemunaitis, Christine Hicking, Jamie Shaw, Remigiusz Kal..., J Clin Oncol, 1/1/2018
Change in neutrophil to lymphocyte ratio during treatment with immune checkpoint inhibitors predicts survival in patients with advanced cancer.
Mingjia Li, Claire F. Verschraegen, SITC (Society for Immunotherapy of Cancer) 33rd Annual Meeting, 1/1/2018
A first in human, dose escalation trial of MSC2363318A - a dual p70S6K/Akt inhibitor, for patients with advanced malignancies.
Verschraegen C, TAT (Targeted Anticancer Therapies) 2015 Poster Awards, 1/4/2015
SWOG S9005: Double blind phase III randomized trial of the anti-progestin agent mifepristone in the treatment of unresectable meningioma.
Yongli Ji, Cathryn J Rankin, Steven M. Grunberg, Andy Sherrod, Jamshid Ahmadi, Lynn G. Feun, Ruth Fredericks, Christy Ann Russell, Fairooz F. Kabbinavar, Keith Stelzer..., J Clin Oncol, 1/1/2015
Choosing wisely: The utility and costs of routine staging imaging in breast cancer.
Samuel Merrill, Pamela Stevens, Claire F. Verschraegen, Marie Wood, J Clin Oncol, 1/1/2015
Randomized phase II pilot study of loratadine for the prevention of bone pain caused by Abstract 9628.
Julia Moukharskaya, Deborah Michelle Abrams, Farrah B. Khan, Joanna Schwartz, Steven Ades, Takamaru Ashikaga, Thomas H. Openshaw, Claire F. Verschraegen, Steven M. Gru..., J Clin Oncol, ASCO Annual Meeting, 1/1/2014
A first-in-human phase I study of CZ48, a lactone ring protected oral camptothecin, in patients with advanced solid tumors.
Devalingam Mahalingam, Montaser F. Shaheen, John Sarantopoulos, Steven Weitman, Beppino C. Giovanella, Zhisong Cao, Douglas Coil, Constantine Markides, Lucy Liu, Clair..., J Clin Oncol, ASCO Annual Meeting, 1/1/2013
Signet ring cell carcinomas do not harbor anaplastic lymphoma kinase (ALK) translocations.
Jill Miller M.D., Zhihua Peng Ph.D., Rebecca Wilcox M.D., Mark Evans Ph.D., Kumarasen Cooper M.D. and Claire Verschraegen M.D., J Clin Oncol, ASCO Annual Meeting, 1/1/2013
Recognizing Chemotherapy Related Reversible Posterior Leukoencephalopathy Syndrome: A Case Report And Literature Review.
Ji Y, Ades S, Verschraegen C, NNECOS (Northern New England Clinical Oncology Society) Annual Meeting, 1/1/2013
A phase I open-label study of Ad-RTS-hIL-12, an adenoviral vector engineered to express hIL-12 under the control of an oral activator ligand, in subjects with unresect...
Gerald P. Linette, Omid Hamid, Eric D. Whitman, John J. Nemunaitis, Jason Chesney, Sanjiv S. Agarwala, Alexander Starodub, John A Barrett, Andrew Marsh, Lori A. Martel..., J Clin Oncol, 1/1/2013
PICASSO 3: A phase 3 international randomized double-blind, placebo-controlled study of doxorubicin plus palifosfamide vs dox plus placebo for patients in first-line f...
Ryan CW, et al, ESMO (European Society for Medical Oncology), 1/1/2013
OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the trea...
Robert Hans Ingemar Andtbacka, Frances A. Collichio, Thomas Amatruda, Neil N. Senzer, Jason Chesney, Keith A. Delman, Lynn E. Spitler, Igor Puzanov, Susan Doleman, Yin..., J Clin Oncol, 1/1/2013
Proposed Phase IB study of optimal cytoreductive surgery and hyperthermic intraoperative peritoneal chemotherapy (HIPEC) with the combination of carboplatin and irinot...
Claire Verschraegen, Brian Loggie, Laura Lambert, Seventh International Symposium on Regional Cancer Therapies, Captiva, FL, 1/18/2012
Management of peritoneal carcinomatosis from well differentiated neuroendocrine tumors of gastrointestinal tract or unknown primary origin: an invited expert opinion s...
Francesco Serafini, Thomas K Weber, Marcovalerio Melis, Sherif Abdel-Misih, Dan Blazer III, Terence Chua, Marcello Deraco, Jesus Esquivel, Antos Frantisek, Martin Good..., Seventh International Symposium on Regional Cancer Therapies, Captiva, FL, 1/18/2012
First-in-human study of AMG 900, an oral pan-Aurora kinase inhibitor, in adult patients (pts) with advanced solid tumors.
Michael Anthony Carducci, Montaser F. Shaheen, Channing Judith Paller, Julie E. Bauman, Nilofer Saba Azad, Poornima Shubhakar, Rui Tang, Mark Stroh, Gregory R. Friberg..., J Clin Oncol, ASCO Annual Meeting, 1/1/2012
Phase I study of irinotecan and temsirolimus in patients with refractory sarcomas.
S. Movva, T. Bocklage, B. Schmit, R. Quinn, B. J. Liem, C. F. Verschraegen, J Clin Oncol, 1/1/2011
A phase I study evaluating the pharmacokinetics of components of S-1 in pts with varying degrees of renal function.
M. W. Saif, M. Lichinitser, M. S. Gordon, B. R. Tan, M. E. Scheulen, N. B. Pandya, J. Sarantopoulos, J. J. Rinehart, C. F. Verschraegen, H. Lenz, C. Zergebel, K. Saito, J Clin Oncol, 1/1/2011
Pegylated liposomal doxorubicin with bevacizumab in the treatment of platinum-resistant ovarian cancer: Toxicity profile results.
S Czok, A Jewell, S Shawki, L Boyd, H Smith, S Blank, C Muller, C Verschraegen, F. Muggia, Gynecologic Oncology, 1/1/2011
A phase 1 study of LY2523355, an Eg5 inhibitor, administered on Days 1, 2, and 3 with or without pegfilgrastim in patients with advanced malignancy (NCT01214629).
Claire Verschraegen, Roger B. Cohen Anthony J. Olszanski, Montaser Shaheen, Yuko Nishida, Julie Bauman, Lily Li, John T. Brandt, Aejaz Nasir, Scott M. Hynes, Jennifer ..., Molecular Cancer Therapeutics, 1/1/2011
Caveolin-1 expression in low-malignant potential (LMP) and epithelial ovarian cancers (EOC).
Verschraegen CF, International Gynecologic Cancer Society Conference, Prague, Czech Republic, 1/21/2010
Phase I/II Study of the Combination of Docetaxel, Gemcitabine, and Bevacizumab in Patients with Advanced or Recurrent Soft Tissue Sarcoma.
Verschraegen CF, Connective Tissue Oncology Society, 1/11/2010
Chemotherapy of the future in platinum resistant disease.
Verschraegen CF, ASCO (American Society of Clinical Oncology), Chicago, IL, 1/6/2010
Join now to see all

Lectures

Growing Your Academic Enterprise
ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
Consequences of Cancer
James Cancer Hospital, Columbus, OH - 1/14/2018
Overian Cancer
Columbus, OH - 1/5/2018
Molecular signatures in the Practice of Oncology.
Burlington, VT - 1/27/2015
Sarcoma
1/26/2015
Lung Cancer
1/19/2015
Ovarian Cancer Ontogenesis
Augusta, GA - 1/17/2015
Emerging therapies in lung cancer.
Burlington, VT - 1/15/2015
Melanoma
1/9/2015
Genomics in Oncology
1/9/2015
Cervical/Endometrial Cancer
1/25/2014
Reducing the Burden of Colon Cancer in Vermont.
Burlington, VT - 1/15/2014
Colon Cancer Epidemiology
Burlington, VT - 1/15/2014
"Integrated Lung Cancer Screening in Vermont"
Burlington, VT - 1/12/2014
"Lung cancer prevention."
Montpelier, VT - 1/10/2014
"Lung Cancer Screening: Coming to a Practice Near You"
1/10/2014
"Cancer and pregnancy"
1/9/2014
"Cancer Treatment in Pregnancy"
1/9/2014
"ASCO Highlights Sarcoma and Gynecologic Cancers"
Burlington, VT - 1/8/2014
"Clinical Research with the NCI, What is the NCTN?"
Burlington, VT - 1/8/2014
"Melanoma"
1/26/2013
"Lung Cancer"
1/25/2013
"Phase 1 clinical studies: What is it?"
Stowe, VT - 1/25/2013
Gynecologic cancers.
Burlington, VT - 1/21/2013
"Cancer Population Health: Exploring Opportunities for Vermont Cancer Center/Vermont Department of Health Collaborations"
1/18/2013
Join now to see all

Other

Peritoneal mesothelioma: Debulking or not?
Verschraegen CF, Pro & Con Debate, Intraperitoneal Therapies Meeting
Lake Tahoe, NV - 1/19/2011
Focus on Sarcoma.
S Movva & C. Verschraegen, New Mexico Cancer Alliance Newsletter
1/1/2010
Fall and Rise of the Vermont Cancer Center
Verschraegen CF, Burlington Free Press
http://archive.burlingtonfreepress.com/article/20121001/NEWS02/310010006/The-fall-and-rise-of-the-Vermont-Cancer-Center
1/1/2002
Present knowledge of gynecologic sarcoma management.
Verschraegen CF, Edwards CL, Fox H, Selected Readings in General Surgery
1/1/2001
Etude du developpement des metastases a partir d'un melanome malin d'origine humaine inocule dans un modele animal.
C. Verschraegen, Bulletin de la Federation Belge des Femmes Diplomees des Universites
1/1/1986
Join now to see all

Authored Content

Focus on Ewing Sarcoma – Time for a Change in the Standards of Care?June 2022

Press Mentions

FDA Approves Biosimilar Bevacizumab-Adcd for the Treatment of Six Types of CancerSeptember 30th, 2022
Shop TalkAugust 10th, 2017
Avelumab Shows Promise as Frontline Immunotherapy Alternative in NSCLCJanuary 11th, 2017
Join now to see all

Professional Memberships

American Association for Cancer Research - AACR
Member
American College of Physicians - ACP
Member
American Society of Clinical Oncologists - ASCO
Member

Other Languages

French, Spanish

Industry Relationships

Director, The Ohio State University Comprehensive Cancer CenterDirector of the Division of Medical Oncology2017 - Present